Share

September 15, 2020; 95 (11) Article

Association of education with Aβ burden in preclinical familial and sporadic Alzheimer disease

Julie Gonneaud, Christophe Bedetti, Alexa Pichet Binette, Tammie L.S. Benzinger, John C. Morris, Randall J. Bateman, Judes Poirier, John C.S. Breitner, Sylvia Villeneuve, for the DIAN Study Group and the PREVENT-AD Research Group
First published August 5, 2020, DOI: https://doi.org/10.1212/WNL.0000000000010314
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
54

Share

Article Information

vol. 95 no. 11 e1554-e1564
DOI: 
https://doi.org/10.1212/WNL.0000000000010314
PubMed: 
32759192
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received July 2, 2019
  • Accepted in final form March 23, 2020
  • First Published August 5, 2020.

Article Versions

Copyright & Usage: 
© 2020 American Academy of Neurology

Author Disclosures

    1. Julie Gonneaud, PhD,
    2. Christophe Bedetti, MSc,
    3. Alexa Pichet Binette, MSc,
    4. Tammie L.S. Benzinger, MD, PhD,
    5. John C. Morris, MD,
    6. Randall J. Bateman, MD,
    7. Judes Poirier, PhD, MD (Hon),
    8. John C.S. Breitner, MD, MPH,
    9. Sylvia Villeneuve, PhD;
    10. for the DIAN Study Group and the PREVENT-AD Research Group
  1. Julie Gonneaud, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Christophe Bedetti, MSc,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Alexa Pichet Binette, MSc,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Tammie L.S. Benzinger, MD, PhD,
    5. Scientific Advisory Boards:

    1. (1) Advisory board, Eisai

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Radiologic Society of North America, travel to grant review (2) Alzheimer's Association International Convention (AAIC) 2017, 2018, 2019, 2020 travel (invited speaker)

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Unpaid consulting, ADMDx, Siemens, Eli Lilly, Eisai.

    Speakers' Bureaus:

    1. Biogen

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Investigator initiated research grants, Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly). Support for the research projects only, no personal compensation or salary support. (2) Roche - participation as site investigator in clinical trials (3) Biogen - participation as site investigator in clinical trials (4) J&J - participation as site investigator in clinical trials (5) Lilly - participation as site investigator in clinical trials (7) Eisai- participation as site investigator in clinical trials

    Research Support, Government Entities:

    1. (1) NIH funded research

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Barnes-Jewish Hospital Foundation (2) Foundation for the ASNR (3) Hope Center (4) Alzheimer's Association

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. John C. Morris, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institute on Aging grants P50AG005681; P01AG003991; P01AG026276; UF1AG032438

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. 1. Clinical Dementia Rating assessment tool (pharma-sponsored clinical trials of investigational drugs for Alzheimer disease 2. AD8 assessment tool (pharma-sponsored clinical trials of investigational drugs for Alzheimer disease)

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Randall J. Bateman, MD,
    7. Scientific Advisory Boards:

    1. (1) C2N Diagnostics, present (2) World Dementia Council, 2018

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Salk Institute for Biological Studies - Adler Meeting - travel. (2) Rainwater Foundation - Tau Consortium - travel (3) Alzheimer's Association - travel (4) Roche - travel and honoraria (5) AC Immune - travel and honoraria (6) American Neurological Association - travel (7) Eisai - honoraria

    Editorial Boards:

    1. (1) The Journal for the Prevention of Alzheimer Disease, Editorial Board 2014-present

    Patents:

    1. (1)Holtzman, DM, Bateman, RJ, Kim, J, inventors; Washington University in St. Louis, assignee. Methods for measuring the metabolism of CNS derived biomolecules in vivo. US Patent Application 12/267,974. June 4, 2009. (2)Bateman, RJ, Holtzman, DM, inventors; The Washington University, assignee. Fluctuations in Amyloid Beta as a Biomarker for Alzheimer’s Disease. US Patent Application PCT/US2008/086529. June 18, 2009. (3) Bateman, RJ, Wildsmith, KR, Dobrowolska, J, Munsell, L,Mawuenyega, K, inventors; The Washington University, assignee. Methods for simultaneously measuring the in vivo metabolism of two or more isoforms of a biomolecule. US Patent Application PCT/US2009/064146. May 20, 2010. US Patent Application 13/129,036. December 1, 2011. (4) Bateman, RJ, Holtzman, DM, inventors; The Washington University, assignee. Methods for Measuring the Metabolism of Neurally Derived Biomolecules in Vivo. US Patent 7,892,845. October 2, 2008. US Patent 8,232,107. July 31, 2012 US Patent Application 14/224,993. July 17, 2014. (5) Bateman, RJ, Holtzman, DM, Mawuenyega, K, inventors; The Washington University, assignee. Methods of determining amyloid beta turnover in blood. US Patent Application PCT/US2011/037754. June 26, 2012. US Patent Application 13/699,497. May 9, 2013. (6) Bateman, RJ, Mawuenyega, K, Ovod, V, Bareiss, A, Kasten, T, Holtzman, DM, inventors; The Washington University, assignee. Methods for Detecting Amyloid Beta Amyloidosis. US Patent Application PCT/US2016/0178646. US Patent Application 15/057,694. June 23, 2016 (7)Bateman, RJ, Patterson, BW, Elbert, DL, inventors; Washington University, assignee. Methods of Diagnosing Amyloid Pathologies Using Analysis of Amyloid-Beta Enrichment Kinetics. US Patent Application PCT/US2013/071042. May 30, 2014. (8) Bateman, RJ, inventor; Washington University, assignee. Plasma Based Methods for Detecting CNS Amyloid Deposition. US Patent Application 62/492,718. May 1, 2017. US Patent Application 62/515,294. June 5, 2017.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Washington University School of Medicine Charles F. and Joanne Knight Distinguished Professor of Neurology, 2012-present (2) A4, Site Principal Investigator, 2014 to present (3) Washington University School of Medicine, Professor of Neurology, 2015 (4) Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU), Director, 2011-Present (5) Dominantly Inherited Alzheimer's Network (DIAN), Director, 2013-present

    Consultancies:

    1. (1) Roche (2) AC Immmune (3) Eisai

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Eli Lilly (2) Roche (3) Janssen (4) DIAN Pharmaceutical Consortium (Biogen, Eisai, Lilly/Avid, Roche/Genentech, United Neuroscience, Janssen) (5) Abbvie (6) Avid (7) Biogen

    Research Support, Government Entities:

    1. (1) NIH R01AG053798, Advisor, 2017-present (2) NIH R01NS095773, PI, 2016-present (3) NIH/NIA U01AG042791, PI, 2013-present (4) NIH/NIA R01AG046179, PI, 2014-present (5) NIH/NIA UF1AG032438, PI, 2008-present (6) NIH R01AG053267, PI, 2017-present (7) NIH U19AG010483, Site PI, 2012-present (8) NIH R01AG061900(R01NS065667), PI, 2008-present (9) NIH U01AG059798, Co-Investigator, 2018-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) BrightFocus Foundation (2) Cure Alzheimer's Fund (3) Association for Frontotemporal Degeneration (4) Rainwater Foundation (5) Alzheimer's Association (6) GHR Foundation (7) Anonymous Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. C2N Diagnostics

    License fee payments, Technology or Inventions:

    1. C2N Diagnostics, Washington University

    Royalty Payments, Technology or Inventions:

    1. C2N Diagnostics, Washington University

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Judes Poirier, PhD, MD (Hon),
    8. Scientific Advisory Boards:

    1. 1) Fondation Alzheimer (France)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) NYU, Speaker, Symposium on Alzheimer, honorarium.

    Editorial Boards:

    1. Journal of Alzheimer's Disease, Associate Editor, 2017- 2019

    Patents:

    1. NONE

    Publishing Royalties:

    1. Young and Centanarian, Trécarré (Canada), 2017 Alzheimer's Disease: The Complete Guide, 2012 La Maladie d'Alzheimer : Trécarré, (Canada), 2020

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. J.L. Levesque Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. John C.S. Breitner, MD, MPH,
    9. Scientific Advisory Boards:

    1. (1) Mayo Clinic Studies on Aging, Scientific Advisory Board(NIH-funded program)(2) Data and Safety Monitoring Board, SPRINT-MIND clinicaltrial (NIA / NHLBI sponsor)(3) Chair, DSMB, for MTI biotech Phase 1 trial

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Receive occasional honoraria for industry-sponsored talks

    Editorial Boards:

    1. Alzheimer's Disease and Associated Disorders, EditorialBoard, 2003 - present;PLOS-One, Academics, 2009 - present;Alzheimer's and Dementia, Editorial Board, 2007 - present;

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research Support (gift) from Pfizer Canada

    Research Support, Government Entities:

    1. (1) Fonds de Recherche du Quebec - SantePI 2012-2015CIHR 2019-

    Research Support, Academic Entities:

    1. (1) Program support from McGill University Faculty of Medicine

    Research Support, Foundations and Societies:

    1. (2) Research support from the Douglas Hospital Research Centre and the Douglas Hospital Foundation.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Sylvia Villeneuve, PhD;
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Canadian Institutes of Health Research, post-doctoral fellowship, 02/12 to 01/15

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. for the DIAN Study Group and the PREVENT-AD Research Group
  1. From the Department of Psychiatry (J.G., C.B., A.P.B., J.P., J.C.S.B., S.V.), McGill University; Douglas Mental Health University Institute (J.G., C.B., A.P.B., J.P., J.C.S.B., S.V.), StoP-AD Centre, Montreal, Canada; Knight Alzheimer's Disease Research Center (T.L.S.B., J.C.M., R.J.B.); and Washington University School of Medicine (T.L.S.B., J.C.M., R.J.B.), St. Louis, MO.
  1. Correspondence
    Dr. Villeneuve sylvia.villeneuve{at}mcgill.ca or Dr. Gonneaud julie.gonneaud{at}mail.mcgill.ca
View Full Text

Article usage

Article usage: August 2020 to September 2020

AbstractFullPdfSource
Aug 20201003030Highwire
Sep 20205373224Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me